NASDAQ · Biotechnology

CMPX (CMPX) Stock

$1.89 -4.55% NASDAQ: CMPX Healthcare

Valuation

MetricValue
Price$1.89
Market Cap$340.37M
P/E Ratio-4.71
P/B Ratio1.39
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$6.88
52-Week Low$1.61
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-33.50%
ROA-30.00%
ROCE-37.06%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio15.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-82.0M$-42.0M$-50.0M$-57.0M$-73.0M
Net Profit$-82.0M$-39.0M$-42.0M$-49.0M$-66.0M
EPS$-1.31$-0.35$-0.33$-0.36$-0.42
Op Margin———-6661.8%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$154.0M$200.0M$157.0M$140.0M$220.0M
Total Liabilities$14.0M$18.0M$8.0M$15.0M$23.0M
Cash$145.0M$35.0M$24.0M$43.0M$31.0M
Borrowings$4.0M$3.0M$2.0M$7.0M$10.0M

Latest News

Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) Insider Monkey · Jul 3, 2026 How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing Insider Monkey · Jun 17, 2026 Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win MarketBeat · Jun 8, 2026 Compass Therapeutics to Participate in Upcoming June Investor Events GlobeNewswire · May 28, 2026 Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting GlobeNewswire · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-20.0M$-34.0M$-41.0M$-45.0M$-49.0M
Investing Cash Flow$-3.0M$-152.0M$27.0M$47.0M$-93.0M
Financing Cash Flow$0$0$0$-1.0M$-1.0M
Net Cash Flow$97.0M$-110.0M$-11.0M$19.0M$-13.0M
Free Cash Flow$-21.0M$-34.0M$-41.0M$-45.0M$-49.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-19.97%
Quick Ratio19.04
Interest Coverage—
Return 1Y-36.34%
Return 3Y-15.54%
Return 5Y-55.31%

Ownership

Insiders Held12.46%
Institutions Held93.79%
Institutions Float Held107.14%
Institutional HolderSharesReport Date
Tang Capital Management, LLC16,790,8092026-03-31
Orbimed Advisors LLC.15,219,9942026-03-31
Suvretta Capital Management, LLC14,307,3792026-03-31
Vivo Capital, LLC9,545,4662026-03-31
Blackrock Inc.9,506,0802026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
FULC $3.73 +0.13% -5.17 $201.56M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%

About CMPX

CMPX is led by CEO Thomas J. Schuetz, employs 35 people, headquartered in US, publicly traded since 2021.

CMPX stock trades at $1.89 with a market capitalization of $340.37M. The stock is valued at a price-to-earnings (P/E) ratio of -4.71, price-to-book of 1.39, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.61 and $6.88, and currently trades 72.5% below its 52-week high.

On profitability, CMPX generates a return on equity (ROE) of -33.50%, return on capital employed of -37.06%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides